Kymera Therapeutics, Inc. Stock Price, News & Analysis

Kymera Therapeutics, Inc. (NASDAQ: KYMR) announced its participation in the 41^st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 9:00 AM PST. CEO Nello Mainolfi will discuss the company's advancements and goals for 2023. Kymera is pioneering targeted protein degradation, developing innovative small molecule therapies to address previously inaccessible disease targets. Its pipeline includes candidates targeting IRAK4, IRAKIMiD, STAT3, and MDM2, aimed at treating various immune-inflammatory diseases and cancers. A live webcast will be available on their website.

Kymera Therapeutics (NASDAQ: KYMR) has reported promising results from its KT-474 Phase 1 clinical trial for hidradenitis suppurativa (HS) and atopic dermatitis (AD). The study demonstrated significant IRAK4 knockdown in blood and skin lesions, alongside a favorable safety profile. Notably, after four weeks of dosing, a majority of patients showed substantial clinical improvement. Following these results, Sanofi has committed to advancing KT-474 into Phase 2 trials. The company is also progressing with its oncology programs, including KT-413, KT-333, and KT-253.

Kymera Therapeutics (NASDAQ: KYMR) announced promising preclinical data at the ASH Annual Meeting regarding the efficacy of its STAT3 and IRAKIMiD degraders for treating specific blood cancers. Study results showed that a STAT3 degrader led to significant disease improvement in a model of cutaneous T-cell lymphoma (CTCL). Additionally, combining IRAKIMiDs with a BCL-2 inhibitor demonstrated strong antitumor effects in MYD88-mutant diffuse large B-cell lymphoma (DLBCL). These findings support the progression of both compounds into clinical trials.

Kymera Therapeutics (NASDAQ: KYMR) presented promising preclinical data for KT-253 at the ASH Annual Meeting, demonstrating its capability to induce rapid apoptosis and tumor regression in acute myeloid leukemia (AML) models. The data indicates that KT-253, in combination with the BCL-2 inhibitor venetoclax, yields durable tumor responses, even in venetoclax-resistant models. The compound also shows potential in other hematologic malignancies, such as DLBCL. Kymera anticipates entering clinical trials for KT-253, aimed at advancing treatment options for wild-type p53 cancers.

Kymera Therapeutics (NASDAQ: KYMR) announced a virtual investor event scheduled for December 14, 2022, where they will share clinical updates on their Phase 1 trial of the IRAK4 degrader KT-474. This trial targets patients with hidradenitis suppurativa or atopic dermatitis. Additionally, the company will discuss its oncology pipeline developments. Kymera focuses on targeted protein degradation to develop innovative therapies for various diseases, leveraging its proprietary Pegasus platform.

Kymera Therapeutics (NASDAQ: KYMR) announced substantial developments in its clinical programs and financial status. The company completed the patient cohort of the KT-474 Phase 1 trial, focusing on autoimmune diseases, and is on track for regulatory submissions for KT-253. In Q3 2022, Kymera raised $150 million in private equity, closing with a cash balance of $596 million, projected to sustain operations into 2025. However, collaboration revenues fell to $9.6 million from $20.3 million year-over-year, contributing to a net loss of $43 million.

Kymera Therapeutics (NASDAQ: KYMR) appointed Dr. Victor Sandor to its Board of Directors on November 3, 2022, to leverage his extensive experience in biopharmaceutical clinical development. Dr. Sandor, previously Chief Medical Officer at Array BioPharma, is expected to enhance Kymera’s capabilities in advancing targeted protein degradation therapies. The company acknowledged the contributions of retiring board member Don Nicholson, PhD, who has served for five years. Kymera aims to capitalize on its Pegasus platform to develop innovative treatments for various diseases.

Kymera Therapeutics (NASDAQ: KYMR) will announce its Q3 2022 financial results on November 3, 2022, hosting a conference call at 8:30 a.m. ET. The company is also set to participate in several investor conferences, including:

• Credit Suisse Annual Healthcare Conference on November 9
• Stifel Healthcare Conference on November 15
• Piper Sandler Healthcare Conference from November 29 to December 1
• Bank of America Biotech Conference on December 7

Access the call at kymeratx.com.

Kymera Therapeutics (NASDAQ: KYMR) has completed dosing in Part C of its Phase 1 clinical trial for KT-474, aimed at treating hidradenitis suppurativa (HS) and atopic dermatitis (AD). This Phase 1 trial showcases positive pharmacokinetics and safety results. Concurrently, the company continues dose escalation for KT-333 and KT-413, both targeting cancer indications. Additionally, IND enabling studies for KT-253 are complete, with an expected IND filing by year-end. A webcast on December 14 will present further details on clinical data and development pipelines.